We are live on ! Find out more
TNXP icon

Tonix Pharmaceuticals
TNXP

15 hedge funds and large institutions have $85.3M invested in Tonix Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

64% more capital invested

Capital invested by funds: $52M → $85.3M (+$33.3M)

60% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 5

25% more funds holding

Funds holding: 12 → 15 (+3)

0% more ownership

Funds ownership: 0% → 0% (+0%)

Holders
15
Holders Change
+3
Holders Change %
+25%
% of All Funds
0.26%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
4
Reduced
2
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$21.3M
2
State Street
State Street
Massachusetts
+$5.88M
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$2.94M
4
Norges Bank
Norges Bank
Norway
+$2.94M
5
Northern Trust
Northern Trust
Illinois
+$2.94M

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$1.47M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$1.01M
3
Citadel Advisors
Citadel Advisors
Florida
-$776K
4
ECM
ExodusPoint Capital Management
New York
-$735K
5
Millennium Management
Millennium Management
New York
-$735K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of America
26
Bank of America
North Carolina
$171K – – –
MIM
27
MetLife Investment Management
New Jersey
$150K – – –
VOYA Investment Management
28
VOYA Investment Management
Georgia
$144K – – –
JP Morgan Chase
29
JP Morgan Chase
New York
$139K – – –
WG
30
Winton Group
United Kingdom
$137K – – –
Principal Financial Group
31
Principal Financial Group
Iowa
$125K – – –
MLICM
32
Metropolitan Life Insurance Company (MetLife)
New York
$115K – – –
EDRH
33
Edmond de Rothschild Holding
Switzerland
$111K – – –
EMG
34
ETF Managers Group
New Jersey
$111K – – –
Invesco
35
Invesco
Georgia
$95K – – –
ProShare Advisors
36
ProShare Advisors
Maryland
$94K – – –
SO
37
STRS Ohio
Ohio
$84K – – –
PPA
38
Parametric Portfolio Associates
Washington
$72K – – –
Victory Capital Management
39
Victory Capital Management
Texas
$58K – – –
AB
40
Amalgamated Bank
New York
$51K – – –
MA
41
MONECO Advisors
Connecticut
$39K – – –
Goldman Sachs
42
Goldman Sachs
New York
$37K – – –
Legal & General Group
43
Legal & General Group
United Kingdom
$29K – – –
T. Rowe Price Associates
44
T. Rowe Price Associates
Maryland
$29K – – –
AIP
45
Ameritas Investment Partners
Nebraska
$28K – – –
FMBTD
46
First Midwest Bank Trust Division
Illinois
$28K – – –
TRCT
47
Tower Research Capital (TRC)
New York
$27K – – –
GPFA
48
Game Plan Financial Advisors
Ohio
$25K – – –
Royal Bank of Canada
49
Royal Bank of Canada
Ontario, Canada
$25K – – –
HighTower Advisors
50
HighTower Advisors
Illinois
$23K – – –
1
2
3 4

TNXP Hedge Fund Activity: Q2 2021 in Review

15 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Tonix Pharmaceuticals (TNXP) for Q2 2021, worth a combined $85.3M — up 64% from $52M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new TNXP positions and 5 closed out — a net gain of 3 holders — while 4 added to existing stakes and 2 trimmed.

The largest buyer was BlackRock, adding an estimated $21.3M. The largest seller was Renaissance Technologies, cutting an estimated $1.47M.

  • 15 institutional investors held Tonix Pharmaceuticals (TNXP) as of Q2 2021, up from 12 in Q1 2021.
  • Funds reported $85.3M of Tonix Pharmaceuticals stock for Q2 2021, up 64% quarter-over-quarter.
  • 8 funds opened new Tonix Pharmaceuticals positions in Q2 2021 and 5 closed out, a net change of +3 holders.
  • The largest Tonix Pharmaceuticals buyer in Q2 2021 was BlackRock, an estimated $21.3M added.
  • The largest Tonix Pharmaceuticals seller in Q2 2021 was Renaissance Technologies, an estimated $1.47M sold.

Based on aggregated 13F filings for Q2 2021.